According to data from Benzinga Pro, during Q2, Myomo's (AMEX:MYO) reported sales totaled $3.10 million. Despite a 11.35% increase in earnings, the company posted a loss of $2.60 million.
Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb
Gainers
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) jumped 125.3% to close at $18.77 on Tuesday after the company announced positive interim results from the Phase 1 trial with FTX-6058 in healthy adult volunteers.
Gainers
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) climbed 79.3% to $14.93 after the company announced positive interim results from the Phase 1 trial with FTX-6058 in healthy adult volunteers.
Myomo (AMEX:MYO) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.60) by 23.33 percent. This is a 58.93 percent increase over losses of $(1.12) per share from the same
Companies Reporting Before The Bell
• Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million.